Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 9—September 2021
Synopsis

Seroprevalence and Virologic Surveillance of Enterovirus 71 and Coxsackievirus A6, United Kingdom, 2006–2017

Everlyn KamauComments to Author , Dung Nguyen, Cristina Celma, Soile Blomqvist, Peter Horby, Peter Simmonds, and Heli Harvala
Author affiliations: University of Oxford, Oxford, UK (E. Kamau, D. Nguyen, P. Horby, P. Simmonds); Public Health England, London, UK (C. Celma); National Institute for Health and Welfare, Helsinki, Finland (S. Blomqvist); National Health Service Blood and Transplant, London, UK (H. Harvala); University College London, London, UK (H. Harvala)

Main Article

Table

EV-A71– and CVA6-positive samples submitted to the Public Health England Enteric Virus Reference Department, United Kingdom, 2006–2017*

Virus Blood CSF Gastrointestinal Respiratory Skin Tissue Total
EV-A71 24 (6.3) 100 (26.2) 122 (32) 46 (12.1) 21 (5.5) 25 (6.6) 381
CVA6 42 (4.1) 44 (4.3) 84 (8.1) 136 (13.2) 759 (73.4) 19 (1.8) 1,084

*Totals of positive samples are given as no. (%). CSF, cerebrospinal fluid; CVA6, coxsackievirus A6; EV-A71, enterovirus A71.

Main Article

Page created: July 15, 2021
Page updated: August 17, 2021
Page reviewed: August 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external